N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma

Diagnostic Pathology

Felix Bremmer²  Heinz-Joachim Radzun²  Arne Strauss¹  Bernhard Hemmerlein²  Carl Ludwig Behnes² 

[1] Department of Urology, University of Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Germany;Department of Pathology, University of Göttingen, Robert-Koch-Str. 40, 37083, Göttingen, Germany

关键词: Immunohistochemistry;    Papillary renal cell carcinoma (RCC);    Histological subtypes;    N-cadherin;   

Others  :  808011
DOI  :  10.1186/1746-1596-7-95

 received in 2012-07-09, accepted in 2012-08-05,  发布年份 2012

【 摘 要 】

Background

Papillary renal cell carcinoma (RCC) represents a rare tumor, which is divided, based on histological criteria, into two subtypes. In contrast to type I papillary RCC type II papillary RCC shows a worse prognosis. So far, reliable immunohistochemical markers for the distinction of these subtypes are not available.

Methods

In the present study the expression of N(neural)-, E(epithelial)-, P(placental)-, und KSP(kidney specific)-cadherin was examined in 22 papillary RCC of histological type I and 18 papillary RCC of histological type II (n = 40).

Results

All papillary RCC type II displayed a membranous expression for N-cadherin, whereas type I did not show any membranous positivity for N-cadherin. E-cadherin exhibited a stronger, but not significant, membranous as well as cytoplasmic expression in type II than in type I papillary RCC. A diagnostic relevant expression of P- and KSP-cadherin could not be demonstrated in both tumor entities.

Conclusion

Thus N-cadherin represents the first immunhistochemical marker for a clear cut differentiation between papillary RCC type I and type II and could be a target for therapy and diagnostic in the future.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2011556982761733 webcite

【 授权许可】

   
2012 Behnes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
• [2]Mydlo JH, Bard RH: Analysis of papillary renal adenocarcinoma. Urology 1987, 30:529-534.
• [3]Delahunt B, Eble JN: Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 1997, 10:537-544.
• [4]Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H: Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998, 153:1467-1473.
• [5]Sanders ME, Mick R, Tomaszewski JE, Barr FG: Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol 2002, 161:997-1005.
• [6]Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS: Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2009, 15:1162-1169.
• [7]Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM: Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001, 32:590-595.
• [8]Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ: Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000, 89:604-614.
• [9]Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M, Debre B, Amsellem-Ouazana D: Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007, 69:230-235.
• [10]Angst BD, Marcozzi C, Magee AI: The cadherin superfamily: diversity in form and function. Journal of cell science 2001, 114:629-641.
• [11]Potter E, Bergwitz C, Brabant G: The cadherin-catenin system: implications for growth and differentiation of endocrine tissues. Endocr Rev 1999, 20:207-239.
• [12]Stemmler MP: Cadherins in development and cancer. Mol Biosyst 2008, 4:835-850.
• [13]Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL: E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998, 185:262-266.
• [14]Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA: Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. The Journal of cell biology 2000, 148:779-790.
• [15]Eble JN: International Agency for Research on Cancer: Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC-Press; 2004.
• [16]Leroy X, Zini L, Leteurtre E, Zerimech F, Porchet N, Aubert JP, Gosselin B, Copin MC: Morphologic subtyping of papillary renal cell carcinoma: correlation with prognosis and differential expression of MUC1 between the two subtypes. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2002, 15:1126-1130.
• [17]Truong LD, Shen SS: Immunohistochemical diagnosis of renal neoplasms. Archives of pathology & laboratory medicine 2011, 135:92-109.
• [18]Skinnider BF, Folpe AL, Hennigar RA, Lim SD, Cohen C, Tamboli P, Young A, de Peralta-Venturina M, Amin MB: Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 2005, 29:747-754.
• [19]Perret AG, Clemencon A, Li G, Tostain J, Peoc’h M: Differential expression of prognostic markers in histological subtypes of papillary renal cell carcinoma. BJU Int 2008, 102:183-187.
• [20]Zhou M, Roma A, Magi-Galluzzi C: The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clinics in laboratory medicine 2005, 25:247-257.
• [21]Avery AK, Beckstead J, Renshaw AA, Corless CL: Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000, 24:203-210.
• [22]Medeiros LJ, Michie SA, Johnson DE, Warnke RA, Weiss LM: An immunoperoxidase study of renal cell carcinomas: correlation with nuclear grade, cell type, and histologic pattern. Hum Pathol 1988, 19:980-987.
• [23]Biddlestone LR, Fleming S: Morphological evidence that A-CAM is a major intercellular adhesion molecule in human kidney. J Pathol 1991, 164:9-15.
• [24]Biddlestone LR, Fleming S: Calcium dependence of A-CAM function in human renal epithelium. J Pathol 1992, 166:163-169.
• [25]Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA: Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumori 2001, 87:173-178.
• [26]Leckband D, Prakasam A: Mechanism and dynamics of cadherin adhesion. Annu Rev Biomed Eng 2006, 8:259-287.
• [27]Hatta K, Takagi S, Fujisawa H, Takeichi M: Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos. Dev Biol 1987, 120:215-227.
• [28]Kalluri R: EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Investig 2009, 119:1417-1419.
• [29]Harada KI, Miyake H, Kusuda Y, Fujisawa M: Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int 2012.
• [30]Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ: N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. The Journal of cell biology 1999, 147:631-644.
• [31]Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273.
• [32]Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005, 65:9455-9462.
• [33]Han AC, Soler AP, Knudsen KA, Salazar H: Distinct cadherin profiles in special variant carcinomas and other tumors of the breast. Hum Pathol 1999, 30:1035-1039.
• [34]Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR: Cadherin switching. Journal of cell science 2008, 121:727-735.
• [35]Yamauchi M, Yoshino I, Yamaguchi R, Shimamura T, Nagasaki M, Imoto S, Niida A, Koizumi F, Kohno T, Yokota J, et al.: N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. American journal of cancer research 2011, 1:823-833.
• [36]Wong AS, Maines-Bandiera SL, Rosen B, Wheelock MJ, Johnson KR, Leung PC, Roskelley CD, Auersperg N: Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. International journal of cancer Journal international du cancer 1999, 81:180-188.
• [37]Horstmann M, Geiger LM, Vogel U, Schmid H, Hennenlotter J, Kuehs U, Merseburger AS, Kruck S, Stenzl A, Bedke J: Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential? World journal of urology 2011, 30(4):525-531.
• [38]Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD: Cadherin switching in ovarian cancer progression. International journal of cancer Journal international du cancer 2003, 106:172-177.
• [39]Chartier NT, Oddou CI, Laine MG, Ducarouge B, Marie CA, Block MR, Jacquier-Sarlin MR: Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer. Cancer Res 2007, 67:9781-9790.
• [40]Cheung LW, Leung PC, Wong AS: Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene 2010, 29:2427-2440.
• [41]Mariotti A, Perotti A, Sessa C, Ruegg C: N-cadherin as a therapeutic target in cancer. Expert opinion on investigational drugs 2007, 16:451-465.